Total Payments
$41,164
2024 Payments
$3,300
Companies
12
Transactions
77
Medicare Patients
38,811
Medicare Billing
$1.1M
Payment Breakdown by Category
Consulting$27,374 (66.5%)
Other$5,600 (13.6%)
Travel$4,069 (9.9%)
Research$1,825 (4.4%)
Food & Beverage$1,401 (3.4%)
Education$874.20 (2.1%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $27,374 | 8 | 66.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,600 | 3 | 13.6% |
| Travel and Lodging | $4,069 | 11 | 9.9% |
| Unspecified | $1,825 | 2 | 4.4% |
| Food and Beverage | $1,401 | 24 | 3.4% |
| Education | $874.20 | 28 | 2.1% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
General
$39,339
75 transactions
Research
$1,825
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $12,433 | 51 | $0 (2017) |
| BioCryst Pharmaceuticals, Inc. | $10,983 | 5 | $0 (2024) |
| Seqirus USA Inc | $6,650 | 3 | $0 (2021) |
| GlaxoSmithKline, LLC. | $6,399 | 1 | $0 (2018) |
| Janssen Research & Development, LLC | $3,200 | 1 | $0 (2019) |
| PFIZER INC. | $1,137 | 8 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $148.66 | 3 | $0 (2020) |
| Novavax Inc | $97.09 | 1 | $0 (2023) |
| La Jolla Pharmaceutical Company | $44.15 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $37.69 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,300 | 1 | BioCryst Pharmaceuticals, Inc. ($3,300) |
| 2023 | $1,988 | 5 | BioCryst Pharmaceuticals, Inc. ($1,825) |
| 2021 | $2,543 | 4 | Seqirus USA Inc ($2,450) |
| 2020 | $17.91 | 1 | Merck Sharp & Dohme Corporation ($17.91) |
| 2019 | $7,409 | 4 | Seqirus USA Inc ($4,200) |
| 2018 | $7,485 | 7 | GlaxoSmithKline, LLC. ($6,399) |
| 2017 | $18,421 | 55 | Alexion Pharmaceuticals, Inc. ($12,433) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/11/2024 | BioCryst Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 10/25/2023 | Roche Diagnostics Corporation | cobas HBV/HCV/HIV-1 Control Kit (Device) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: Molecular Diagnostics | ||||||
| 10/13/2023 | Novavax Inc | — | Food and Beverage | In-kind items and services | $97.09 | General |
| 10/12/2023 | La Jolla Pharmaceutical Company | — | Food and Beverage | In-kind items and services | $44.15 | General |
| 06/28/2023 | BioCryst Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $825.00 | Research |
| Study: A Phase 3 study to evaluate the safety and pharmacokinetics of Berotralstat Prophylaxis in children with hereditary andiodema who are 2 to < 12 years of age | ||||||
| 01/05/2023 | BioCryst Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A Phase 3, single-arm, open-label study to evaluate the safety and pharmacokinetics of intravenous peramivir in pediatric subjects from birth to 6 months of age infected with influenza A or B | ||||||
| 12/08/2021 | PFIZER INC. | PREVNAR 13 (Biological) | Food and Beverage | In-kind items and services | $36.97 | General |
| Category: VACCINES | ||||||
| 09/03/2021 | PFIZER INC. | PREVNAR 13 (Biological) | Food and Beverage | In-kind items and services | $36.40 | General |
| Category: VACCINES | ||||||
| 07/13/2021 | Seqirus USA Inc | — | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| 06/03/2021 | PFIZER INC. | — | Gift | In-kind items and services | $20.00 | General |
| 02/19/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: VACCINE | ||||||
| 12/18/2019 | Seqirus USA Inc | FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) (Biological) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Vaccines | ||||||
| 04/17/2019 | PFIZER INC. | PREVNAR - 13 (Biological), TRUMENBA | Food and Beverage | In-kind items and services | $8.54 | General |
| Category: VACCINES | ||||||
| 01/25/2019 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 01/22/2019 | Seqirus USA Inc | FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) (Biological) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Vaccines | ||||||
| 09/10/2018 | PFIZER INC. | PREVNAR - 13 (Biological) | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: VACCINES | ||||||
| 08/24/2018 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Food and Beverage | In-kind items and services | $37.69 | General |
| Category: IMMUNOLOGY | ||||||
| 07/11/2018 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $393.50 | General |
| 06/21/2018 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Consulting Fee | Cash or cash equivalent | $6,398.81 | General |
| Category: VACCINES | ||||||
| 03/03/2018 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $390.82 | General |
| 03/03/2018 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $237.82 | General |
| 01/25/2018 | AstraZeneca Pharmaceuticals LP | SYNAGIS (Biological) | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: Respiratory | ||||||
| 10/06/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $121.16 | General |
| 09/19/2017 | Alexion Pharmaceuticals, Inc. | Kanuma (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 08/24/2017 | Alexion Pharmaceuticals, Inc. | Kanuma (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, single-arm, open-label study to evaluate the safety and pharmacokinetics of intravenous peramivir in pediatric subjects from birth to 6 months of age infected with influenza A or B | BioCryst Pharmaceuticals, Inc. | $1,000 | 1 |
| A Phase 3 study to evaluate the safety and pharmacokinetics of Berotralstat Prophylaxis in children with hereditary andiodema who are 2 to < 12 years of age | BioCryst Pharmaceuticals, Inc. | $825.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 193 | 193 | $14,475 | $7,459 |
| 2022 | 10 | 2,658 | 2,676 | $199,590 | $96,191 |
| 2021 | 10 | 35,927 | 36,015 | $1.6M | $946,451 |
| 2020 | 1 | 33 | 33 | $1,320 | $525.36 |
Total Patients
38,811
Total Services
38,917
Medicare Billing
$1.1M
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 163 | 163 | $12,225 | $6,300 | 51.5% |
| 0134A | Adm sarscv2 bvl 50mcg/.5ml a | Office | 2023 | 30 | 30 | $2,250 | $1,160 | 51.5% |
| 0004A | Adm sarscov2 30mcg/0.3ml bst | Office | 2022 | 1,279 | 1,291 | $96,825 | $47,032 | 48.6% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 841 | 841 | $63,075 | $30,310 | 48.1% |
| 0064A | Adm sarscov2 50mcg/0.25mlbst | Office | 2022 | 240 | 242 | $18,150 | $8,823 | 48.6% |
| 0134A | Fee covid-19 vac 14 res | Office | 2022 | 145 | 145 | $10,875 | $5,226 | 48.1% |
| 0001A | Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 30 mcg/0.3ml dosage, diluent reconstituted; first dose | Office | 2022 | 28 | 28 | $2,100 | $1,028 | 49.0% |
| 0002A | Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 30 mcg/0.3ml dosage, diluent reconstituted; second dose | Office | 2022 | 28 | 28 | $2,100 | $1,027 | 48.9% |
| 0003A | Adm sarscov2 30mcg/0.3ml 3rd | Office | 2022 | 27 | 27 | $2,025 | $985.66 | 48.7% |
| 0013A | Adm sarscov2 100mcg/0.5ml3rd | Office | 2022 | 26 | 26 | $1,950 | $949.25 | 48.7% |
| 90471 | Administration of vaccine | Office | 2022 | 33 | 37 | $1,665 | $405.90 | 24.4% |
| 0034A | Adm sarscov2 vac ad26 .5ml b | Office | 2022 | 11 | 11 | $825.00 | $404.58 | 49.0% |
| 0002A | Adm sarscov2 30mcg/0.3ml 2nd | Office | 2021 | 12,971 | 12,984 | $523,875 | $377,586 | 72.1% |
| 0001A | Adm sarscov2 30mcg/0.3ml 1st | Office | 2021 | 13,379 | 13,448 | $543,835 | $243,064 | 44.7% |
| 0004A | Fee covid-19 vac 1 res | Office | 2021 | 5,003 | 5,006 | $278,500 | $185,622 | 66.7% |
| 0031A | Adm sarscov2 vac ad26 .5ml | Office | 2021 | 1,824 | 1,826 | $75,000 | $55,714 | 74.3% |
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 754 | 754 | $31,105 | $22,725 | 73.1% |
| 0064A | Fee covid-19 vac 7 res | Office | 2021 | 571 | 571 | $41,460 | $21,173 | 51.1% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 890 | 891 | $37,320 | $20,729 | 55.5% |
| 0013A | Fee covid-19 vac 2 booster | Office | 2021 | 299 | 299 | $15,390 | $11,087 | 72.0% |
| 0034A | Fee covid-19 vac 4 res | Office | 2021 | 194 | 194 | $14,305 | $7,194 | 50.3% |
| 0003A | Fee covid-19 vac 1 booster | Office | 2021 | 42 | 42 | $3,010 | $1,557 | 51.7% |
| 0001A | Adm sarscov2 30mcg/0.3ml 1st | Office | 2020 | 33 | 33 | $1,320 | $525.36 | 39.8% |
About John Vanchiere, MD/PHD
John Vanchiere, MD/PHD is a Pediatric Infectious Diseases healthcare provider based in Shreveport, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871673111.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Vanchiere, MD/PHD has received a total of $41,164 in payments from pharmaceutical and medical device companies, with $3,300 received in 2024. These payments were reported across 77 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($27,374).
As a Medicare-enrolled provider, Vanchiere has provided services to 38,811 Medicare beneficiaries, totaling 38,917 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Infectious Diseases
- Other Specialties Pediatric Infectious Diseases
- Location Shreveport, LA
- Active Since 10/17/2006
- Last Updated 09/28/2007
- Taxonomy Code 2080P0208X
- Entity Type Individual
- NPI Number 1871673111
Products in Payments
- Kanuma (Drug) $12,433
- BEXSERO (Biological) $6,399
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) (Biological) $4,200
- PREVNAR 13 (Biological) $73.37
- ILARIS (Biological) $37.69
- cobas HBV/HCV/HIV-1 Control Kit (Device) $21.59
- PREVNAR - 13 (Biological) $21.20
- GARDASIL 9 (Biological) $17.91
- SYNAGIS (Biological) $13.71
- ZERBAXA (Drug) $9.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.